Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
Svensson J, Lönn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjöström L, Bengtsson BA. Svensson J, et al. Among authors: cerchio k. J Clin Endocrinol Metab. 1998 Feb;83(2):362-9. doi: 10.1210/jcem.83.2.4539. J Clin Endocrinol Metab. 1998. PMID: 9467542 Clinical Trial.
Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ; MK-677/Alendronate Study Group. Murphy MG, et al. Among authors: cerchio k. J Clin Endocrinol Metab. 2001 Mar;86(3):1116-25. doi: 10.1210/jcem.86.3.7294. J Clin Endocrinol Metab. 2001. PMID: 11238495 Clinical Trial.
Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
Codner E, Cassorla F, Tiulpakov AN, Mericq MV, Avila A, Pescovitz OH, Svensson J, Cerchio K, Krupa D, Gertz BJ, Murphy G. Codner E, et al. Among authors: cerchio k. Clin Pharmacol Ther. 2001 Jul;70(1):91-8. doi: 10.1067/mcp.2001.116514. Clin Pharmacol Ther. 2001. PMID: 11452249 Clinical Trial.
Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.
Chapman IM, Pescovitz OH, Murphy G, Treep T, Cerchio KA, Krupa D, Gertz B, Polvino WJ, Skiles EH, Pezzoli SS, Thorner MO. Chapman IM, et al. Among authors: cerchio ka. J Clin Endocrinol Metab. 1997 Oct;82(10):3455-63. doi: 10.1210/jcem.82.10.4297. J Clin Endocrinol Metab. 1997. PMID: 9329386 Clinical Trial.
Pharmacokinetics and food interaction of MK-462 in healthy males.
Cheng H, Polvino WJ, Sciberras D, Yogendran L, Cerchio KA, Christie K, Olah TV, McLoughlin D, James I, Rogers JD. Cheng H, et al. Among authors: cerchio ka. Biopharm Drug Dispos. 1996 Jan;17(1):17-24. doi: 10.1002/(SICI)1099-081X(199601)17:1<17::AID-BDD932>3.0.CO;2-F. Biopharm Drug Dispos. 1996. PMID: 8991488 Clinical Trial.
Effect of a novel histamine subtype-3 receptor inverse agonist and modafinil on EEG power spectra during sleep deprivation and recovery sleep in male volunteers.
James LM, Iannone R, Palcza J, Renger JJ, Calder N, Cerchio K, Gottesdiener K, Hargreaves R, Murphy MG, Boyle J, Dijk DJ. James LM, et al. Among authors: cerchio k. Psychopharmacology (Berl). 2011 Jun;215(4):643-53. doi: 10.1007/s00213-010-2158-3. Epub 2011 Feb 8. Psychopharmacology (Berl). 2011. PMID: 21301819 Clinical Trial.
13 results